Improving the lives of people suffering from mental illness and substance use disorders

What we do

Pharmaceuticals

Pharmaceuticals

Developing innovative medicines for patients, creating value for healthcare providers

Digital Therapeutics

Digital Therapeutics

Pioneering evidence-based therapies, delivering better access for users

Mental illness & substance use disorders

Mental illness & substance use disorders

Focusing on areas of great human suffering with wider societal implications

Key News

APRIL 28, 2022
Interim Report Q1 - Promising start to 2022

APRIL 27, 2022
Orexo´s partner Gesynta Pharma granted Orphan Drug Designation by the FDA for OX-MPI - systemic sclerosis

MODIA™ - our digital therapy for opioid dependence

  • to be used along with pharmaceuticals
  • 6 months treatment
  • grounded in cognitive behavioral therapy techniques
  • available 24/7
  • ongoing clinical trial incl. up to 400 patients

Our history

Strong history paving the way for the future. Learn more about our key milestones since we where founded in Uppsala, Sweden, in 1995.

News Flow

Regulatory Press Releases

Orexo Social

25 May 2022

A week ago at ABG Sundal Collier. Gonzalo A. Castanon, Life Science analyst, is asking about the synergies with com… https://t.co/tsGcz12IfY

23 May 2022

Sustainable companies do not only contribute to a better society, they also reduce operational risks & create long… https://t.co/5mNxAARABq

20 May 2022

Deprexis - one of the most clinical proven #Digital therapies - can help people suffering from #depression. 🔊 Fin…https://t.co/Jt77qQgs5hh

Financial Snapshot

Group net revenues

592  MSEK

LTM1

Group EBITDA

-134 MSEK

LTM1

US Pharma segment EBIT

296 MSEK

LTM1

Cash position

434 MSEK

Q1 2022

1 Last Twelve Months, Q221-Q122, for more information about financial development Link